Beijing Gravel Biopharma Secures Over RMB 600 Million in Series C Financing and Files IPO Prospectus

Today (September 30), Beijing Grit Bio-Medicine Co., Ltd. (hereinafter referred to as "Grit Bio" or "the Company") announced the completion of its Series C financing, with a total financing amount exceeding 600 million yuan.

Grail Bio is an innovative pharmaceutical company established in 2019, focusing on the field of cell therapy. It is committed to developing TIL cell drugs, in vivo CAR-T therapies, and other off-the-shelf cell therapies.Relying on a diversified technology platform and a groundbreaking R&D pipeline, the company has successfully completed multiple rounds of financing, gaining favor and support from several well-known venture capital institutions.

The company has built multiple core technology R&D platforms, including StemTexp.^®Dry TIL Expansion Technology Platform, StaViral^®Virus Stable Transfection Process, ImmuT Finder^®Immune Regulation Target Discovery Platform, KOReTIL^®Efficient Gene Editing Platform andTST hunter^®High-Throughput TCR Discovery Platform。

Relying on these self-innovative technology platforms, Grit Bio has developed multiple TIL cell drugs and universal cell therapies, continuously promoting the iteration and upgrading of cell treatment products.

ItsGT101 Injection, the first TIL cell drug in China to be approved for registration clinical trials, has entered the pivotal Phase II clinical stage.It is expected to submit a new drug marketing application in 2026, and it is hoped that it will become the first commercially available TIL therapy approved for marketing in China.

GT201 Injection, the world's first TIL product developed by the company that combines an expression membrane with an IL-15 complex,Enhancing the persistence and tumor-killing efficacy of T cells in the body through genetic engineering technology. This therapyCompleted IND dual submissions in China and the U.S. and received approval,In 2025, the first patient with advanced squamous cell carcinoma of the head and neck achieved complete tumor remission for six consecutive months, demonstrating significant clinical potential.

In addition, Gracell Biotechnologies has also developed several universal cell therapy products. Among them,GT801 is the next-generation in vivo CAR-T product, leveraging the innovative CLAMP-targeted LNP delivery platform. It features advantages such as no lymphodepletion required, low off-target risk, and high safety, making it more suitable for treating autoimmune diseases.GT719 is the world's first universal CAR-iNKT cell therapy derived from stem cells, which has demonstrated preliminary safety and efficacy signals in treating hematologic tumors and autoimmune diseases in IIT.GT601 is a neoantigen mRNA vaccine for tumors based on high-precision AI prediction and targeted LNP delivery, currently preparing for IIT clinical trials.

E.N.D

ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe team of the WeChat Official Account "Cell and Gene Therapy Field" has established a professional communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also specify.